DE60204067T2 - Verwendung von Xanthenon-4-Essigsäure zur Herstellung eines Medikaments für die Behandlung von hyperproliferativer Störungen - Google Patents

Verwendung von Xanthenon-4-Essigsäure zur Herstellung eines Medikaments für die Behandlung von hyperproliferativer Störungen Download PDF

Info

Publication number
DE60204067T2
DE60204067T2 DE60204067T DE60204067T DE60204067T2 DE 60204067 T2 DE60204067 T2 DE 60204067T2 DE 60204067 T DE60204067 T DE 60204067T DE 60204067 T DE60204067 T DE 60204067T DE 60204067 T2 DE60204067 T2 DE 60204067T2
Authority
DE
Germany
Prior art keywords
acetic acid
xanthenone
mammal
tumor
hyperproliferative tissue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60204067T
Other languages
German (de)
English (en)
Other versions
DE60204067D1 (de
Inventor
David A. Buffalo Bellnier
Thomas J. Grand Island Dougherty
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Health Research Inc
Original Assignee
Health Research Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Health Research Inc filed Critical Health Research Inc
Publication of DE60204067D1 publication Critical patent/DE60204067D1/de
Application granted granted Critical
Publication of DE60204067T2 publication Critical patent/DE60204067T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pathology (AREA)
  • Rheumatology (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Radiation-Therapy Devices (AREA)
DE60204067T 2001-03-07 2002-02-28 Verwendung von Xanthenon-4-Essigsäure zur Herstellung eines Medikaments für die Behandlung von hyperproliferativer Störungen Expired - Fee Related DE60204067T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US801163 1991-11-26
US09/801,163 US6495585B2 (en) 2001-03-07 2001-03-07 Method for treating hyperproliferative tissue in a mammal

Publications (2)

Publication Number Publication Date
DE60204067D1 DE60204067D1 (de) 2005-06-16
DE60204067T2 true DE60204067T2 (de) 2006-01-26

Family

ID=25180358

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60204067T Expired - Fee Related DE60204067T2 (de) 2001-03-07 2002-02-28 Verwendung von Xanthenon-4-Essigsäure zur Herstellung eines Medikaments für die Behandlung von hyperproliferativer Störungen

Country Status (5)

Country Link
US (1) US6495585B2 (cg-RX-API-DMAC7.html)
EP (1) EP1238666B1 (cg-RX-API-DMAC7.html)
JP (1) JP2002325853A (cg-RX-API-DMAC7.html)
AT (1) ATE295163T1 (cg-RX-API-DMAC7.html)
DE (1) DE60204067T2 (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE38994E1 (en) 1988-07-20 2006-02-28 Health Research, Inc. Pyropheophorbides conjugates and their use in photodynamic therapy
USRE39094E1 (en) 1988-07-20 2006-05-09 Health Research, Inc. Pyropheophorbides and their use in photodynamic therapy
US6602274B1 (en) 1999-01-15 2003-08-05 Light Sciences Corporation Targeted transcutaneous cancer therapy
JP2002534483A (ja) * 1999-01-15 2002-10-15 ライト サイエンシーズ コーポレイション 代謝性骨障害または骨転移のための治療的組成物
US20030114434A1 (en) * 1999-08-31 2003-06-19 James Chen Extended duration light activated cancer therapy
US7897140B2 (en) 1999-12-23 2011-03-01 Health Research, Inc. Multi DTPA conjugated tetrapyrollic compounds for phototherapeutic contrast agents
US7166719B2 (en) 2002-06-27 2007-01-23 Health Research, Inc. Fluorinated photosensitizers related to chlorins and bacteriochlorins for photodynamic therapy
US20020049247A1 (en) 2000-01-12 2002-04-25 Chen James C. Novel treatment for eye disease
AU2003249742A1 (en) 2002-07-02 2004-01-23 Health Research, Inc. Efficient synthesis of pyropheophorbide a and its derivatives
WO2008147445A2 (en) * 2006-11-09 2008-12-04 University Of Maryland, Baltimore Use of 5,6-dimethylxanthenone-4-acetic acid as an antimicrobial agent
US8180444B2 (en) * 2007-06-22 2012-05-15 Biolitec Pharma Marketing Ltd Enhanced PhotoDynamic Therapy with immune system assist
US20110201678A1 (en) * 2008-10-17 2011-08-18 Masse Craig E Xanthenone-4-Acetic Acid Derivatives
CN109289048B (zh) * 2018-08-08 2021-05-25 南京工业大学 一种肿瘤血管阻断协同光治疗试剂及其合成方法与应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4649151A (en) * 1982-09-27 1987-03-10 Health Research, Inc. Drugs comprising porphyrins
US5002962A (en) * 1988-07-20 1991-03-26 Health Research, Inc. Photosensitizing agents
GB9308166D0 (en) * 1993-04-20 1993-06-02 Cancer Res Campaign Tech Cancer therapy

Also Published As

Publication number Publication date
JP2002325853A (ja) 2002-11-12
DE60204067D1 (de) 2005-06-16
EP1238666A3 (en) 2004-01-07
ATE295163T1 (de) 2005-05-15
EP1238666B1 (en) 2005-05-11
EP1238666A2 (en) 2002-09-11
US20020128303A1 (en) 2002-09-12
US6495585B2 (en) 2002-12-17

Similar Documents

Publication Publication Date Title
DE69822496T2 (de) Lipidkomplex-lyophilisat von wasserunlöslichen porphyrinen
DE69334009T2 (de) Verfahren zur Aktivierung von photoempfindlichen Mitteln
DE69330277T2 (de) Transkutane in-vivo aktivierung von photoempfindlichen mitteln im blut
DE60023476T2 (de) Kombination von doctaxel und rhumab her2 zur krebsbehandlung
DE69803376T2 (de) Äthylenglykolester von monohydrobenzoporphyrinderivaten als photoaktive mittel
DE69632858T2 (de) Zur verabreichnung einer schlecht wasserlöslichen photosensibilisierenden verbindung geeignete emulsion und deren verwendung
DE3889231T2 (de) Zytotoxische Mittel mit spezifischer Wellenlänge.
DE69429507T2 (de) Magnetisch reagierende zusammensetzung als träger für biologisch aktive substanzen und verfahren für ihre herstellung und verwendung
DE69310014T2 (de) Liposomen mit Porphyrin-Photosensibilisatoren enthaltende Mittel
DE68924215T2 (de) Wellenlängenspeziphisches, cytotoxisches Mittel.
DE69329073T2 (de) In liposomen verkapseltes taxol und verwendungsverfahren
DE69524238T2 (de) Transfer von molekülen in das zytosol von zellen durch photosensibilisierende substanzen
DE69333769T2 (de) Verwendung einer liposomalen zusammensetzung zur herstellung eines medikamentes zur behandlung von entzündlichen zuständen
DE60204067T2 (de) Verwendung von Xanthenon-4-Essigsäure zur Herstellung eines Medikaments für die Behandlung von hyperproliferativer Störungen
DE3875629T2 (de) Interstitielle verabreichung von emulzionen von perfluorierten verbindungen fuer die reoxygenierung von hypoxischen tumorzellen.
DE68920656T2 (de) Verwendung vpn Adenosin-5'-phosphate in der Behandlung von Krebscachexia.
DE69429615T2 (de) Modulationen des immunsystems mittels psoralene, die durch sichtbares licht aktiviert werden
DE69023442T2 (de) Verwendung einer Cyaninfarbe in einem antitumoralen Mittel.
DE60001629T2 (de) Therapeutische zusammensetzungen fur knochenstoffwechselstörungen oder knochenmetastasen enthaltend einen photosensitizer und ein bisphosphonat
DE68905994T2 (de) Koloniestimulierungsfaktor-gelatinkonjugate.
DE3115080A1 (de) Arzneimittel fuer die orale verabreichung und verfahren zu seiner herstellung
DE4310935A1 (de) Mikroemulsionen, deren Herstellung sowie Verwendung bei der Behandlung von Krebserkrankungen
DE3638124A1 (de) Neue pharmazeutische verwendung von ebselen
Schaffer et al. Photofrin II as an efficient radiosensitizing agent in an experimental tumor
EP1019037B1 (de) Delta-aminolävulinsäure enthaltendes arzneimittel

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee